Is CLVR or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Which has stronger valuation & earnings, VRPX or ARDS?

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.31 N/A

Is VRPX or ARDS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Aridis Pharmaceuticals N/A N/A N/A

Is ARDS or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Trevena N/A N/A -119.55%

Which has stronger earnings and valuation, ARDS or NAVB?

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.31 N/A Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A

Is ARDS or NAVB more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A

Which has preferable valuation & earnings, GNCA or ARDS?

Aridis Pharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.31 N/A

Is GNCA or ARDS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A -182.88% -62.76% Aridis Pharmaceuticals N/A N/A N/A

Aridis Pharmaceuticals (ARDS) Competitors

Compare

ARDS vs. CLVR, VRPX, TRVN, NAVB, and GNCA

Should you buy Aridis Pharmaceuticals stock or one of its competitors? MarketBeat compares Aridis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aridis Pharmaceuticals include Clever Leaves (CLVR), Virpax Pharmaceuticals (VRPX), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry.

How does Aridis Pharmaceuticals compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

Clever Leaves has higher revenue and earnings than Aridis Pharmaceuticals. Clever Leaves is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	N/A

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Aridis Pharmaceuticals	Neutral

Clever Leaves has a beta of 3816.13, meaning that its share price is 381,513% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.59, meaning that its share price is 4,659% more volatile than the broader market.

Summary

Clever Leaves beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Virpax Pharmaceuticals has a beta of -16.52, suggesting that its stock price is 1,752% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.59, suggesting that its stock price is 4,659% more volatile than the broader market.

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	N/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Aridis Pharmaceuticals	N/A	N/A	N/A

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Aridis Pharmaceuticals	Neutral

Summary

Aridis Pharmaceuticals beats Virpax Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Trevena?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Trevena	Neutral

Aridis Pharmaceuticals has a beta of 47.59, indicating that its stock price is 4,659% more volatile than the broader market. Comparatively, Trevena has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

Summary

Aridis Pharmaceuticals beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Navidea Biopharmaceuticals	Neutral

Aridis Pharmaceuticals has a beta of 47.59, meaning that its share price is 4,659% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Aridis Pharmaceuticals	Neutral

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	N/A

Aridis Pharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
Aridis Pharmaceuticals	N/A	N/A	N/A

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.59, meaning that its share price is 4,659% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDS vs. The Competition

Export

Metric	Aridis Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5K	$975.11M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	0.00	1.53	27.14	23.64
Price / Sales	N/A	105.75	517.06	88.99
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	N/A	8.47	10.28	6.07
Net Income	-$30.37M	-$2.70M	$3.60B	$331.99M

Aridis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	$5K	N/A	0.00	30	Gap Down
CLVR Clever Leaves	N/A	$0.01 flat	N/A	+3,250.0%	$18K	$17.42M	N/A	560
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	-99.5%	$14K	N/A	N/A	7
TRVN Trevena	N/A	$0.01 +640.0%	N/A	-98.8%	$11K	$443K	N/A	40	Gap Up
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. CLVR, VRPX, TRVN, NAVB, and GNCA

How does Aridis Pharmaceuticals compare to Clever Leaves?

Summary

How does Aridis Pharmaceuticals compare to Virpax Pharmaceuticals?

Summary

How does Aridis Pharmaceuticals compare to Trevena?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Summary

How does Aridis Pharmaceuticals compare to Genocea Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. CLVR, VRPX, TRVN, NAVB, and GNCA

How does Aridis Pharmaceuticals compare to Clever Leaves?

Is CLVR or ARDS more profitable?

Which has better valuation & earnings, CLVR or ARDS?

Do insiders & institutionals hold more shares of CLVR or ARDS?

Does the media refer more to CLVR or ARDS?

Which has more volatility and risk, CLVR or ARDS?

Summary

How does Aridis Pharmaceuticals compare to Virpax Pharmaceuticals?

Which has more risk and volatility, VRPX or ARDS?

Which has stronger valuation & earnings, VRPX or ARDS?

Do institutionals & insiders believe in VRPX or ARDS?

Is VRPX or ARDS more profitable?

Does the media prefer VRPX or ARDS?

Summary

How does Aridis Pharmaceuticals compare to Trevena?

Does the media refer more to ARDS or TRVN?

Which has more volatility and risk, ARDS or TRVN?

Is ARDS or TRVN more profitable?

Do institutionals & insiders believe in ARDS or TRVN?

Which has higher earnings and valuation, ARDS or TRVN?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Do insiders and institutionals hold more shares of ARDS or NAVB?

Does the media prefer ARDS or NAVB?

Which has more risk and volatility, ARDS or NAVB?

Is ARDS or NAVB more profitable?

Which has stronger earnings and valuation, ARDS or NAVB?

Summary

How does Aridis Pharmaceuticals compare to Genocea Biosciences?

Does the media favor GNCA or ARDS?

Do insiders & institutionals have more ownership in GNCA or ARDS?

Which has preferable valuation & earnings, GNCA or ARDS?

Is GNCA or ARDS more profitable?

Which has more volatility and risk, GNCA or ARDS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools